<DOC>
	<DOCNO>NCT00068432</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , use different way stop tumor cell divide stop grow die . Celecoxib may stop growth pancreatic cancer stop blood flow tumor block enzyme necessary tumor cell growth . Combining gemcitabine celecoxib may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together celecoxib work treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine Celecoxib Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall survival 6 month patient metastatic pancreatic cancer treat gemcitabine celecoxib . - Determine objective tumor response , progression-free survival , median survival patient treat regimen . - Determine safety toxicity regimen patient . OUTLINE : This nonrandomized , open-label , multicenter study . Patients receive gemcitabine IV 65 minute day 1 , 8 , 15 oral celecoxib twice daily day 1-28 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow monthly 6 month study entry every 3 month thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 8 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic pancreatic cancer Radiographic evidence disease No known brain metastasis PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Gastrointestinal No history peptic ulcer disease No gastrointestinal bleeding within past 3 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biological composition study drug sulfonamides No prior allergic reaction , asthma , urticaria take aspirin NSAIDs No ongoing active infection No uncontrolled illness No psychiatric illness social situation would preclude study compliance No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy metastatic pancreatic cancer More 6 month since prior neoadjuvant adjuvant chemoradiotherapy ( include gemcitabine ) pancreatic cancer Endocrine therapy Not specify Radiotherapy See Chemotherapy More 6 month since prior radiotherapy Surgery Not specify Other More 30 day since prior investigational agent No concurrent investigational commercial agent therapy malignancy No concurrent nonsteroidal antiinflammatory drug ( NSAIDs ) No concurrent cyclooxygenase2 ( COX2 ) inhibitor ( e.g. , rofecoxib ) Concurrent acetaminophencontaining medication lowdose aspirin ( 325 mg/day ) cardiac prophylaxis allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>